Browsing: III

Phase III trial shows up to 28.7% weight loss, but tolerability remains a key concern for Eli Lilly’s triple-agonist therapy.…

Images of the scalps of two patients treated with the 5% formulation of Cosmo Pharmaceuticals’ androgenetic alopecia (AGA) candidate clascoterone—both…

More than two weeks after Pfizer (NYSE: PFE) and Novo Nordisk (NASDAQ Copenhagen: NOVO-B) slugged it out for Metsera (NASDAQ:…

Credit: Stocktrek Images / Getty Images image of a multiple sclerosis neuron. Roche announced this week that two important Phase…

Credit: TopMicrobialStock / Adobe Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase…